Occult micrometastasis: Enrichment, identification and characterization of single disseminated tumour cells

Seminars in Cancer Biology

Volumn 11, Issue 5, 2001, Pages 327-337

  Pantel, Klaus ^a   Otte, Marcus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bone marrow; Cytokeratin; Micrometastasis; Single cell analysis

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; DISSEMINATED CANCER; METASTASIS; PROGNOSIS; REVIEW; TUMOR CELL;

EID: 0034747733     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0388     Document Type: Article

References (78)

1. The clinical study of micrometastatic cancer by bone biopsy
2. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
3. Detection and clinical importance of micrometastatic disease
4. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
5. Prognostic significance of micrometastatic bone marrow involvement
6. Monoclonal antibodies - New tools in diagnosis and therapy
7. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination
8. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction
9. Limitations of reverse transcriptase-polymerase chain reaction for detection of micrometastatic epithelial cancer cells in bone marrow
10. Prognostic significance of isolated tumor cells in bone marrow of patients with non-small cell carcinomas without overt metastases
11. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging
12. Detection and management of bone marrow micrometastases in breast cancer
13. Meta-analysis of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated
14. Standardisation of the immunocytochemical detection of cancer cells in bone marrow and blood: I. Establishment of objective criteria for the evaluation of immunostained cells
15. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer
16. Molecular detection of micrometastases and circulating tumor cells in solid tumors
17. Circulating micrometastases following oncological surgery
18. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy
19. Tumor cells in blood shed from the surgical field
20. Dissemination of tumor cells in patients undergoing surgery, for colorectal cancer
21. Breast cancer cells in the blood: A pilot study
22. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
23. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy
24. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors
25. Sentinel lymphadenectomy in breast cancer
26. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients
27. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes
28. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients
29. Isolation of prostate-derived single cells and cell clusters from human peripheral blood
30. Increased sensitivity for detection of micrometastases in bone marrow/peripheral-blood stem-cell products from breast cancer patients by negative immunomagnetic separation
31. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood
32. An immunological enrichment method for epithelial cells from peripheral blood
33. Detection and characterization of carcinoma cells in the blood
34. Isolation by size of epithelial tumor cells. A new method for the immunomorphological and molecular characterization of circulating tumor cells
35. Isolation of blood-borne epithelium derived c-erb-B2 oncoprotein-positive clustered cells from peripheral blood of breast cancer patients
36. Detection of rare circulating breast cancer cells by filtration cytometry and identification by DNA content: Sensitivity in an experimental model
37. Nucleic acid-based methods for the detection of cancer
38. Genetic diagnosis of lymph-node metastasis in colorectal cancer
39. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma
40. Diagnosis of micrometastases by the amplification of tissue-specific genes
41. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using RT-PCR
42. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells
43. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
44. Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells
45. Clinical significance of bone marrow metastases as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation
46. Micrometastases and survival in stage II colorectal cancer
47. Detection of circulating carcinoma cells by telomerase activity
48. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells
49. Multiple mutation analyses in single tumor cells with improved whole genome amplification
50. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization
51. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
52. Establishment of micrometastatic carcinoma cell lines: A novel source of tumor cell vaccines
53. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer
54. Regulation and functional role of MHC expression on tumors
55. Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection
56. Urokinase plasminogen activator receptor (uPA-R): One potential characteristic of metastatic phenotypes in minimal residual tumor disease
57. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of state I-III breast cancer patients
58. Cancer vaccines
59. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases
60. p53 mutations are not required for early dissemination of cancer cells
61. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
62. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
63. Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow
64. Prostate cancer and other xenografts from cells in peripheral blood of patients
65. Clinical relevance of the proliferative potential of bone marrow micrometastases in solid tumors
66. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
67. Cytokeratin-positive occult metastatic cells in bone marrow and survival of breast cancer patients with stage I-III disease
68. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up
69. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
70. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
71. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
72. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse
73. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients
74. Micrometastatic tumor cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance
75. Prognostic significance of bone marrow micrometastases in patients with gastric cancer
76. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
77. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma
78. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer